What is the impact of the 2017 cochrane systematic review and meta-analysis that evaluated the use of PCSK9 inhibitors for lowering cardiovascular disease and mortality?

2018 ◽  
Vol 19 (7) ◽  
pp. 739-741 ◽  
Author(s):  
Mohamed A. Jalloh ◽  
Eric J. Ip ◽  
Shadi Doroudgar
Keyword(s):  
Systematic Review ◽  
Cardiovascular Disease ◽  
Meta Analysis ◽  
Pcsk9 Inhibitors ◽  
Cochrane Systematic Review ◽  
The Impact

scholarly journals Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis

Heart ◽  
2020 ◽  
Vol 106 (15) ◽  
pp. 1142-1147 ◽  
Author(s):  
Xintao Li ◽  
Bo Guan ◽  
Tong Su ◽  
Wei Liu ◽  
Mengyao Chen ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cardiovascular Disease ◽  
Hospital Mortality ◽  
Mortality Risk ◽  
Meta Analysis ◽  
Cardiac Injury ◽  
Sensitivity Analyses ◽  
Future Research ◽  
Cardiovascular Comorbidities ◽  
The Impact

BackgroundCoronavirus disease 2019 (COVID-19) has produced a significant health burden worldwide, especially in patients with cardiovascular comorbidities. The aim of this systematic review and meta-analysis was to assess the impact of underlying cardiovascular comorbidities and acute cardiac injury on in-hospital mortality risk.MethodsPubMed, Embase and Web of Science were searched for publications that reported the relationship of underlying cardiovascular disease (CVD), hypertension and myocardial injury with in-hospital fatal outcomes in patients with COVID-19. The ORs were extracted and pooled. Subgroup and sensitivity analyses were performed to explore the potential sources of heterogeneity.ResultsA total of 10 studies were enrolled in this meta-analysis, including eight studies for CVD, seven for hypertension and eight for acute cardiac injury. The presence of CVD and hypertension was associated with higher odds of in-hospital mortality (unadjusted OR 4.85, 95% CI 3.07 to 7.70; I2=29%; unadjusted OR 3.67, 95% CI 2.31 to 5.83; I2=57%, respectively). Acute cardiac injury was also associated with a higher unadjusted odds of 21.15 (95% CI 10.19 to 43.94; I2=71%).ConclusionCOVID-19 patients with underlying cardiovascular comorbidities, including CVD and hypertension, may face a greater risk of fatal outcomes. Acute cardiac injury may act as a marker of mortality risk. Given the unadjusted results of our meta-analysis, future research are warranted.

scholarly journals Prevalence of comorbidity in Chinese patients with COVID-19: systematic review and meta-analysis of risk factors

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Tingxuan Yin ◽  
Yuanjun Li ◽  
Ying Ying ◽  
Zhijun Luo
Keyword(s):  
Systematic Review ◽  
Cardiovascular Disease ◽  
Cerebrovascular Disease ◽  
Meta Analysis ◽  
Treatment Strategies ◽  
Chinese Patients ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Underlying Diseases ◽  
The Impact

Abstract Background Coronavirus disease 2019 (COVID-19) is an infectious disease characterized by cough, fever, and fatigue and 20% of cases will develop into severe conditions resulting from acute lung injury with the manifestation of the acute respiratory distress syndrome (ARDS) that accounts for more than 50% of mortality. Currently, it has been reported that some comorbidities are linked with an increased rate of severity and mortality among COVID-19 patients. To assess the role of comorbidity in COVID-19 progression, we performed a systematic review with a meta-analysis on the relationship of COVID-19 severity with 8 different underlying diseases. Methods PubMed, Web of Science, and CNKI were searched for articles investigating the prevalence of comorbidities in severe and non-severe COVID-19 patients. A total of 41 studies comprising 12,526 patients were included. Results Prevalence of some commodities was lower than that in general population such as hypertension (19% vs 23.2%), diabetes (9% vs 10.9%), chronic kidney disease (CKD) (2% vs 9.5%), chronic liver diseases (CLD) (3% vs 24.8%) and chronic obstructive pulmonary disease (COPD) (3% vs 8.6%), while some others including cancer (1% vs 0.6%), cardiovascular disease (6% vs 1.8%) and cerebrovascular disease (2% vs 0.9%) exhibited greater percentage in COVID-19. Cerebrovascular disease (OR = 3.70, 95%CI 2.51–5.45) was found to be the strongest risk factor in disease exacerbation, followed by CKD (OR = 3.60, 95%CI 2.18–5.94), COPD (OR = 3.14, 95% CI 2.35–4.19), cardiovascular disease (OR = 2.76, 95% CI 2.18–3.49), malignancy (OR = 2.63, 95% CI 1.75–3.95), diabetes (OR = 2.49, 95% CI 2.10–2.96) and hypertension (OR = 2.13, 95% CI 1.81–2.51). We found no correlation between CLD and increased disease severity (OR = 1.32, 95% CI 0.96–1.82). Conclusion The impact of all eight underlying diseases on COVID-19 deterioration seemed to be higher in patients outside Hubei. Based on different comorbidities, COVID-19 patients tend to be at risk of developing poor outcomes to a varying degree. Thus, tailored infection prevention and monitoring and treatment strategies targeting these high-risk subgroups might improve prognosis during the COVID-19 pandemic.

scholarly journals The impact of transcendental meditation on depressive symptoms and blood pressure in adults with cardiovascular disease: A systematic review and meta-analysis

2019 ◽  
Vol 46 ◽  
pp. 172-179 ◽  
Author(s):  
Emily C. Gathright ◽  
Elena Salmoirago-Blotcher ◽  
Julie DeCosta ◽  
Brittany L. Balletto ◽  
Marissa L. Donahue ◽  
...  
Keyword(s):  
Systematic Review ◽  
Blood Pressure ◽  
Cardiovascular Disease ◽  
Depressive Symptoms ◽  
Transcendental Meditation ◽  
Meta Analysis ◽  
The Impact

scholarly journals Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and meta-analysis

2020 ◽  
Author(s):  
Miguel Marques Antunes ◽  
Gonçalo S Duarte ◽  
Dulce Brito ◽  
Margarida Borges ◽  
João Costa ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cardiovascular Disease ◽  
High Risk ◽  
Observational Studies ◽  
Meta Analysis ◽  
Pneumococcal Vaccination ◽  
Significant Heterogeneity ◽  
All Cause Mortality ◽  
The Impact ◽  
Very High

Abstract Aims There are several guidelines that recommend pneumococcal vaccination (PPSV23 and/or PCV13) in adults with a history of cardiovascular disease (established heart failure, coronary disease, and cerebrovascular disease) or at a very high risk of cardiovascular disease. However, there is no randomized controlled trial (RCT) systematic review that evaluates the impact of vaccination on all-cause mortality compared to no vaccination in this particular population. Our objective is to conduct a systematic review and meta-analysis of the impact of pneumococcal vaccination in the referred population. Methods and results We searched CENTRAL and MEDLINE for relevant RCTs and observational studies. Data were screened, extracted, and appraised by two independent reviewers. We pooled results using a random effects model, and used hazard ratios (HRs) with 95% confidence intervals (CIs) to assess measure of effect. The primary outcome was all-cause mortality and we assessed the confidence in the evidence using the GRADE framework. No RCTs were found. Seven observational studies were included for analyses. Pooled results from five studies enrolling a total of 163 756 participants showed a significant decrease in all-cause mortality (HR 0.78, 95% CI 0.73–0.83, very low confidence), without statistically significant heterogeneity (χ2 test P = 0.21; I2 = 32%). Conclusions Pneumococcal vaccination was associated with a 22% decrease of all-cause mortality in patients with cardiovascular disease or at a very high cardiovascular risk. However, limitations due to study design and the serious risk of bias in three of the included studies leads to a decreased level of result confidence.

scholarly journals Cochrane systematic review and meta-analysis of the impact of psychological treatments for people with epilepsy on health-related quality of life

Epilepsia ◽  
2018 ◽  
Vol 59 (2) ◽  
pp. 315-332 ◽  
Author(s):  
Rosa Michaelis ◽  
Venus Tang ◽  
Janelle L. Wagner ◽  
Avani C. Modi ◽  
W. Curt LaFrance ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Systematic Review ◽  
Meta Analysis ◽  
Health Related Quality ◽  
Cochrane Systematic Review ◽  
Psychological Treatments ◽  
Related Quality ◽  
Health Related ◽  
The Impact

scholarly journals Cardiovascular System and SARS-CoV-2: Etiology, Physiopathology and Clinical Presentation: A Systematic Review

2021 ◽  
Author(s):  
Jucier Gonçalves Júnior ◽  
Estelita Lima Cândido ◽  
Gislene Farias de Oliveira ◽  
Modesto Leite Rolim Neto
Keyword(s):  
Systematic Review ◽  
Cardiovascular Disease ◽  
Cardiovascular System ◽  
Clinical Presentation ◽  
Meta Analysis ◽  
Cardiovascular Complications ◽  
Review Of The Literature ◽  
Governmental Organizations ◽  
System A ◽  
The Impact

During SARS-CoV-1 and Middle East Respiratory Distress Syndrome (MERS) outbreaks it was observed a particularly elevated incidence of cardiovascular disease among patients. With COVID-19, this correlation becomes evident again. However, the cardiovascular impacts by COVID-19 pandemic are not yet well established although publications about its potential deleterious effects are constant. Thus, aimed to carry a systematic review of the literature with meta-analysis, the following question was used as a guide: what practical contributions does the scientific literature produced in the period of 2019-2020 has to offer about the impact of the COVID-19 on cardiovascular system? A systematic review of the literature using the Virtual Health Library (VHL) and PubMed with the following descriptors: #1 “cardiovascular disease” [MeSH] AND #2 “COVID-19” [keyword], as well as their equivalents in the Portuguese and Spanish language, during the period from December 2019 to March 2020 was performed. One hundred articles were found in Pubmed and twenty-seven were selected. In VHL there are 59 articles and four were selected totaling thirty-one papers. The findings were then divided into three subcategories: Etiology, Physiopathology and Risk factors of SARS-CoV-2 in Cardiovascular System; Clinical presentation, laboratory markers and imagenological aspects of SARS-CoV-2 in cardiovascular system; and Anti-Hypertensive Drugs, Cardiovascular System and SARS-CoV-2. When it comes to the cardiovascular system, these issues are aggravated and urge as a joint commitment from researchers, medical and governmental organizations to carry out more robust studies with bold methodologies aimed at mapping prognostic factors and assertive therapeutic approaches in the management of cardiovascular complications of COVID- 19.

Sign in / Sign up

Export Citation Format

Share Document